Position in VCEL
as of Mar 31, 2026
· filed May 14, 2026
Position Value
$2,251,900
-$1,961,270 QoQ
Shares Held
70,000
-40.2% QoQ
Ownership
0.137%
of shares outstanding
% of Portfolio
0.28%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Jun 2025
4 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in VCEL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026Rhenman & Partners Asset Management AB holds $297,378,771 across 37 Biotechnology names. VCEL ranks #34 (0.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
48,100 | $37,163,984 | |
| 2 | INSM |
INSMED Inc
|
159,760 | $26,123,955 | |
| 3 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
43,485 | $19,417,791 | |
| 4 | JAZZ |
Jazz Pharmaceuticals plc
|
75,890 | $14,347,004 | |
| 5 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
24,050 | $12,589,453 | |
| 6 | BMRN |
Biomarin Pharmaceutical Inc
|
207,000 | $11,693,430 | |
| 7 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
34,465 | $11,403,434 | |
| 8 | RPRX |
Royalty Pharma plc
|
233,000 | $11,177,010 |
All Filings in VCEL
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $2,251,900 | 70,000 | Shares | Sole | 2026-05-14 | |
| 2025-12-31 | $4,213,170 | 117,000 | Shares | Sole | 2026-02-13 | |
| 2025-09-30 | $3,681,990 | 117,000 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $2,467,900 | 58,000 | Shares | Sole | 2025-08-13 | |
| No filing history on record for this holder in this stock. | ||||||